Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015

Details for Mechanism ID: 12872
Country/Region: Central Asia Region
Year: 2014
Main Partner: Columbia University
Main Partner Program: Mailman School of Public Health
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $1,001,915 Additional Pipeline Funding: $602,200

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

This IM supports PEPFAR Strategy Objective 1, 2, and 3. The implementing mechanism’s (IM) goal is to provide TTA to and build the capacity of the MOHs in CAR so that care, treatment, laboratory, and KPs prevention services for people at risk for, and living with, HIV/AIDS will be provided according to accepted international standards, and adapted to the local context. Objectives: 1) Increase the capacity of MOHs to provide high quality basic HIV care, including HIV treatment with ART and opportunistic infections (OI) treatment and prophylaxis; 2) Increase laboratory capacity of MOHs to provide quality-assured HIV-related laboratory tests; and 3) Increase the capacity of MOHs to provide comprehensive HIV prevention to KPs, including MAT. In ROP14, the IM will continue addressing C&T and MAT assessments’ recommendations and will focus on strengthening technical capacity of staff through updating the clinical protocols, trainings and mentorships in pilots; will advocate for and educate on MAT to address low MAT coverage rate; will integrate HIV services with MAT, and TB; and will improve access to HIV diagnostics including rapid testing. The TA is primarily targeted to PWID, PLWH, and MOH staff. For cost-efficiency, the IM with CAR MOHs will develop SOPs, guidelines and quality management systems, which will be institutionalized and incorporated into MOH’s “Prikaz” (orders) to be implemented nationwide, after appropriate USG-supported training and mentoring of relevant staff. Columbia University/New York and CDC plan to evaluate the project activities in ROP14. USG will monitor the IM through regular monitoring visits, meetings and monthly reports. CDC plans to start a new Cooperative Agreement with local organization to continue activities started under this IM.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $450,000
Care: TB/HIV (HVTB) $100,000
Laboratory Infrastructure (HLAB) $1,915
Testing: HIV Testing and Counseling (HVCT) $250,000
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $100,000
Treatment: Adult Treatment (HTXS) $100,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 3,750
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 850
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 400
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 2,500
CARE_SITE Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 11
CARE_SITE Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 5
CARE_SITE Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 2
CARE_SITE Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 4
CARE_SITE Total number of PEPFAR supported sites providing clinical care services 2015 14
CARE_SITE Total number of PEPFAR supported sites providing clinical care services 2015 5
CARE_SITE Total number of PEPFAR supported sites providing clinical care services 2015 3
CARE_SITE Total number of PEPFAR supported sites providing clinical care services 2015 6
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 600
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 330
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 120
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 150
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 105
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 35
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 30
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 40
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 595
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 315
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 120
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2015 160
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2015 700
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2015 350
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2015 150
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2015 200
LAB_CAP By site support type: Technical Assistance-only (TA) 2015 4
LAB_CAP By site support type: Technical Assistance-only (TA) 2015 4
LAB_CAP By site support type: Technical Assistance-only (TA) 2015 5
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 13
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 4
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 4
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 5
LAB_CAP Sum of Site Support Type disaggregates 2015 4
LAB_CAP Sum of Site Support Type disaggregates 2015 4
LAB_CAP Sum of Site Support Type disaggregates 2015 5
QI_SITE Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months 2015 14
QI_SITE Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months 2015 5
QI_SITE Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months 2015 3
QI_SITE Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months 2015 6
QI_SITE Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC 2015 14
QI_SITE Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC 2015 5
QI_SITE Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC 2015 3
QI_SITE Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC 2015 6
SITE_SUPP By program area/support type: Care and Support Technical Assistance-only (TA) 2015 14
SITE_SUPP By program area/support type: Care and Support Technical Assistance-only (TA) 2015 5
SITE_SUPP By program area/support type: Care and Support Technical Assistance-only (TA) 2015 3
SITE_SUPP By program area/support type: Care and Support Technical Assistance-only (TA) 2015 6
SITE_SUPP By program area/support type: HTC Technical Assistance-only (TA) 2015 14
SITE_SUPP By program area/support type: HTC Technical Assistance-only (TA) 2015 4
SITE_SUPP By program area/support type: HTC Technical Assistance-only (TA) 2015 5
SITE_SUPP By program area/support type: HTC Technical Assistance-only (TA) 2015 5
SITE_SUPP By program area/support type: Key Populations Prevention Technical Assistance-only (TA) 2015 14
SITE_SUPP By program area/support type: Key Populations Prevention Technical Assistance-only (TA) 2015 4
SITE_SUPP By program area/support type: Key Populations Prevention Technical Assistance-only (TA) 2015 5
SITE_SUPP By program area/support type: Key Populations Prevention Technical Assistance-only (TA) 2015 5
SITE_SUPP By program area/support type: Lab Technical Assistance-only (TA) 2015 13
SITE_SUPP By program area/support type: Lab Technical Assistance-only (TA) 2015 4
SITE_SUPP By program area/support type: Lab Technical Assistance-only (TA) 2015 4
SITE_SUPP By program area/support type: Lab Technical Assistance-only (TA) 2015 5
SITE_SUPP By program area/support type: Treatment Technical Assistance-only (TA) 2015 14
SITE_SUPP By program area/support type: Treatment Technical Assistance-only (TA) 2015 5
SITE_SUPP By program area/support type: Treatment Technical Assistance-only (TA) 2015 3
SITE_SUPP By program area/support type: Treatment Technical Assistance-only (TA) 2015 6
SITE_SUPP Number of unique sites supported by PEPFAR 2015 31
SITE_SUPP Number of unique sites supported by PEPFAR 2015 10
SITE_SUPP Number of unique sites supported by PEPFAR 2015 9
SITE_SUPP Number of unique sites supported by PEPFAR 2015 12
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 2,210
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 710
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 250
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 1,250
Cross Cutting Budget Categories and Known Amounts Total: $200,000
Human Resources for Health $200,000